US Patent Issued to Vasgene Therapeutics on July 7 for "Treatment of cancers using sEphB4-HSA fusion proteins" (California Inventor)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,090, issued on July 7, was assigned to Vasgene Therapeutics Inc (Los Angeles).

"Treatment of cancers using sEphB4-HSA fusion proteins" was invented by Valery Krasnoperov (Pasadena, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods are provided for treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a polypeptide agent that inhibits EphB4 or EphrinB2 mediated functions. In various embodiments the methods further provide administration of a therapeutically effective amount of an immune checkpoint inhibitor. The present inventors have demonstrated that the synergistic ef...